ストックスクリーナーアプリを入手
87.05
0.62%
-0.5595
前日終値:
$87.61
開ける：
$87.74
24時間の取引高:
193.52K
Relative Volume:
0.25
時価総額：
$5.97B
収益：
$217.17M
当期純損益:
$-202.68M
株価収益率:
-37.80
EPS:
-2.3028
ネットキャッシュフロー:
$-156.63M
1週間 パフォーマンス:
-1.42%
1か月 パフォーマンス:
-5.68%
6か月 パフォーマンス:
-16.76%
1年 パフォーマンス:
+31.57%
1日の値動き範囲:
$86.98
$89.33
1週間の範囲:
$82.89
$89.33
52週間の値動き範囲:
$60.70
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
名前
Rhythm Pharmaceuticals Inc
セクター
電話
857-264-4280
住所
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
87.05 | 6.01B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
452.77 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.56 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
885.99 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.75 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
150.13 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-19 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-11-25 | 開始されました | Citigroup | Buy |
| 2025-11-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-07-07 | 開始されました | Leerink Partners | Outperform |
| 2025-04-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2025-01-02 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Oppenheimer | Outperform |
| 2024-10-21 | 開始されました | Guggenheim | Buy |
| 2024-09-18 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-17 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-08-08 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-05 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 繰り返されました | Needham | Buy |
| 2022-03-02 | 再開されました | Stifel | Buy |
| 2022-02-17 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 再開されました | Goldman | Neutral |
| 2021-08-04 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-08-04 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-01-08 | 開始されました | Goldman | Sell |
| 2019-07-12 | アップグレード | Stifel | Hold → Buy |
| 2019-07-08 | 開始されました | Canaccord Genuity | Buy |
| 2019-03-13 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-09-07 | 再開されました | Morgan Stanley | Overweight |
| 2018-06-25 | 繰り返されました | Needham | Buy |
| 2018-06-15 | 繰り返されました | Needham | Buy |
| 2017-10-30 | 開始されました | BofA/Merrill | Buy |
| 2017-10-30 | 開始されました | Needham | Buy |
すべてを表示
Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース
Rhythm Pharmaceuticals stock rating reaffirmed by Citizens - Investing.com Canada
Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine - Seeking Alpha
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for - Eastern Progress
PTC Therapeutics Drops 6.3% Amid Sector-Wide Selling - AlphaStreet
Rhythm Pharmaceuticals, Inc. (RYTM): Investor Outlook Reveals 56% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
RYTM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
What Does the FDA's PDUFA Extension Signal for Rhythm Pharmaceuticals - Kavout
Rhythm Pharmaceuticals to Present Seven Abstracts at ENDO 2026, Highlighting Advances in Treatment for Rare Neuroendocrine Diseases - Quiver Quantitative
Inside Rhythm’s seven ENDO 2026 talks on hypothalamic obesity, PWS, BBS - Stock Titan
Rhythm Algorithm Aims To Clarify Bardet Biedl Diagnosis And Market Potential - Sahm
Breakeven On The Horizon For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Moomoo
Why Rhythm Pharmaceuticals stock triumphed on Tuesday - MSN
New Bardet-Biedl diagnostic guide tackles years-long diagnosis delays - Stock Titan
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics - Sahm
(RYTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Rhythm Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - The Manila Times
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 57% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Rhythm Pharmaceuticals CAO Christopher German sells $428,131 in stock - Investing.com India
Rhythm Pharmaceuticals CAO Christopher German sells $428,131 in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) officer sells 4,643 shares after exercising options - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
Rhythm Pharmaceuticals, Inc. (RYTM): Exploring a 52.67% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Perceptive-affiliated holders report 5.1% stake in Rhythm (RYTM) - Stock Titan
Liquidity Mapping Around (RYTM) Price Events - Stock Traders Daily
Expanded EU IMCIVREE Label for Hypothalamic Obesity Could Be A Game Changer For Rhythm (RYTM) - Sahm
Rhythm Pharmaceuticals, Inc.Common Stock (NQ: RYTM - FinancialContent
Rhythm Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $149 - Moomoo
Green Thumb Just Made an Unprecedented Move. Here's What It Means for GTBIF Investors. - The Motley Fool
RYTM: Strong HO launch, global reach, and next-gen therapies drive growth in rare obesity markets - TradingView
RYTM: Strong HO launch, robust pipeline, and next-gen therapies to address key patient needs - TradingView
HC Wainwright Issues Pessimistic Outlook for RYTM Earnings - MarketBeat
Comerica Bank Cuts Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
New Setmelanotide Data Shapes Rhythm Pharmaceuticals Obesity Growth Story - Sahm
Guggenheim Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143 - 富途牛牛
Guggenheim Remains a Buy on Rhythm Pharmaceuticals (RYTM) - The Globe and Mail
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology - marketscreener.com
Hidden hunger in rare obesity: new UK study finds severe hyperphagia missed - Stock Titan
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $105 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Gem with 46.76% Upside Potential - DirectorsTalk Interviews
Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
RYTM Maintained by Canaccord Genuity -- Price Target Raised to $143 - GuruFocus
Rhythm Pharmaceuticals Price Target Raised to $143.00/Share From $140.00 by Canaccord Genuity - Moomoo
Rhythm Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-05-07 - Seeking Alpha
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results - Sahm
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $143 - Moomoo
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2026 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals Q1 2026 Earnings: Stock Rises 8% on Imcivree Revenue BeatNews and Statistics - IndexBox
Rhythm Pharmaceuticals Inc (RYTM) 財務データ
収益
当期純利益
現金流量
EPS
0.12%
0.82%
大文字化:
|
ボリューム (24 時間):